The stock's rise snapped a four-day losing streak.

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company with a market capitalization of $77 million, announced on Monday the appointment of Ian Hodgson as the new Chief ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said ...

H.C. Wainwright lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $50 from $75 and keeps a Buy rating on the shares. The firm ...